Logotype for PHAXIAM Therapeutics SA

PHAXIAM Therapeutics (PHXM) investor relations material

PHAXIAM Therapeutics Q3 2024 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for PHAXIAM Therapeutics SA
Q3 2024 earnings summary13 Nov, 2024

Executive summary

  • Cash and cash equivalents reached €5.7 million as of September 30, 2024, following a €7.8 million capital increase in July 2024.

  • Clinical strategy execution remains on track, with the GLORIA global Phase II study protocol approved by the U.S. FDA and patient recruitment planned for Q1 2025.

  • PHAXIAM is developing phage therapies targeting resistant bacteria responsible for most hospital-acquired infections.

Financial highlights

  • Cash position increased from €1.5 million on June 30, 2024, to €5.7 million on September 30, 2024.

  • Net proceeds from the July 2024 capital increase amounted to €6.8 million after costs.

  • Current cash runway is expected to fund operations until March 2025.

Outlook and guidance

  • Patient recruitment for the GLORIA Phase II study is expected to begin in Q1 2025.

  • First patient enrollment in the Phase II DFU study anticipated in Q4 2024.

  • Preliminary results from the Phase I endocarditis study expected around mid-2025.

  • Exploring cost reduction, non-dilutive funding, and strategic investments to extend cash runway.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing innovative treatments for drug-resistant bacterial infections. Leveraging phages, which are viruses that specifically target and kill bacteria, the company is developing a portfolio aimed at combating some of the most challenging and resistant bacterial strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is also involved in advancing clinical-stage therapies, including eryaspase, which is being tested in late-stage clinical trials for conditions such as pancreatic cancer and acute lymphoblastic leukemia. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage